Program
etilagimod alpha
Also written as “eftilagimod alpha”, “IMP321” and “IMP321 (eftilagimod alpha)”.
Its studies are mostly in Breast Neoplasms · Squamous Cell Carcinoma of Head and Neck · Carcinoma, Non-Small-Cell Lung · Melanoma · Carcinoma, Renal Cell, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Immutep S.A.S. | 101 open or running | phase 3since Feb 2, 2023 | Jul 7, 2006 | Jun 2027phase 3 · NCT06726265 |
| Immutep Australia Pty. | 10 open or running | phase 1since Feb 2, 2016 | Feb 2, 2016 | none ahead |
Also a collaborator on its studies: Merck and umanis.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 7, 2006First studies: 4 phase 1 studiesNew to Immutep S.A.S.Immutep S.A.S. · NCT00349934, NCT00351949, NCT00354861 and 1 more
- Nov 5, 2015Phase 2 study in Adenocarcinoma Breast Stage IVImmutep S.A.S. · NCT02614833 · 242 enrolled · Belgium, France, Germany and more
- Feb 2, 2016Immutep Australia Pty.'s first study: phase 1 study in MelanomaNew to Immutep Australia Pty.Immutep Australia Pty. · NCT02676869 · 24 enrolled · Australia
- Jul 16, 2018Phase 2 study in Squamous Cell Carcinoma of Head and NeckImmutep S.A.S. · NCT03625323 · 187 enrolled · United States
- Jan 29, 2020Phase 1 study in Breast NeoplasmsImmutep S.A.S. · NCT04252768
- Mar 19, 2021Phase 2 study in Squamous Cell Carcinoma of Head and NeckImmutep S.A.S. · NCT04811027 · 171 enrolled · United States, Australia, Belgium and more
- Feb 2, 2023Phase 3 study in Breast NeoplasmsImmutep S.A.S. · NCT05747794 · 72 enrolled · United States, Belgium, Georgia and more
- Dec 3, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungImmutep S.A.S. · NCT06726265 · 756 enrolled · United States, Argentina, Australia and more
Ahead
- Jun 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungImmutep S.A.S. · NCT06726265
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06726265Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | Immutep S.A.S. | Jun 2027 | 756 |
| NCT05747794Breast Neoplasms · United States, Belgium, Georgia and more | 3 | Terminated | Immutep S.A.S. | Apr 30, 2026 | 72 |
| NCT04811027Squamous Cell Carcinoma of Head and Neck · United States, Australia, Belgium and more | 2 | Completed | Immutep S.A.S. | Mar 11, 2024 | 171 |
| NCT04252768Breast Neoplasms | 1 | Withdrawn | Immutep S.A.S. | Jun 2025 | 0 |
| NCT03625323Squamous Cell Carcinoma of Head and Neck · United States | 2 | Completed | Immutep S.A.S. | Jun 2, 2022 | 187 |
| NCT02676869Melanoma · Australia | 1 | Completed | Immutep Australia Pty. | Aug 2019 | 24 |
| NCT02614833Adenocarcinoma Breast Stage IV · Belgium, France, Germany and more | 2 | Completed | Immutep S.A.S. | Mar 2020 | 242 |
| NCT00354861Healthy · France | 1 | Completed | Immutep S.A.S. | Nov 2005 | 48 |
| NCT00354263Healthy · France | 1 | Completed | Immutep S.A.S. | Sep 2005 | 60 |
| NCT00351949Carcinoma, Renal Cell · France | 1 | Completed | Immutep S.A.S. | Aug 2008 | 24 |
| NCT00349934Breast Neoplasms · France | 1 | Completed | Immutep S.A.S. | Nov 2009 | 33 |
How it is read
Names in the registry
- “eftilagimod alpha”, 3 entries
- “IMP321”, 3 entries
- “IMP321 (eftilagimod alpha)”, 2 entries
- “eftilagimod alfa”, 1 entry
- “Eftilagimod Alpha”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 3 studies
- Squamous Cell Carcinoma of Head and Neck, 2 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
- Melanoma, 1 study
- Carcinoma, Renal Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.